Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:40:11 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Z:BMY - BRISTOL-MYERS SQUIBB CO - http://www.bristolmyers.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMY - Z9.061.71·69.000.361.99+2.4554.117,117.11,044,24488,05260.00  62.05  59.7763.33  42.5219:59:29Feb 0515 min RT 2¢

Recent Trades - Last 10 of 88052
Time ETExPriceChangeVolume
19:59:29Z61.752.23200
19:54:45Z61.752.2375
19:51:44Z61.712.1950
19:49:39Z61.902.382
19:48:06Z61.73942.219415
19:47:21Z61.712.191
19:36:14Z61.712.19200
19:34:31Z61.882.36100
19:32:17Z61.892.372
19:26:58Z61.712.1920

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 06:59U:BMYNews ReleaseBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
2026-02-04 06:59U:BMYNews ReleaseBristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
2026-02-03 06:59U:BMYNews ReleaseBristol Myers Squibb Introduces "Change the Target. Change What's Possible." to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
2026-01-22 07:00U:BMYNews ReleaseBristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
2026-01-20 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
2026-01-12 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
2026-01-02 06:59U:BMYNews ReleaseBristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference
2025-12-19 15:05U:BMYNews ReleaseBristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
2025-12-18 06:59U:BMYNews ReleaseBristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
2025-12-11 06:59U:BMYNews ReleaseU.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo(TM) (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
2025-12-10 16:16U:BMYNews ReleaseBristol Myers Squibb Announces Dividend Increase
2025-12-08 16:30U:BMYNews ReleaseBristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
2025-12-04 20:15U:BMYNews ReleaseBristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
2025-12-03 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
2025-12-01 06:59U:BMYNews ReleaseBristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
2025-11-26 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference
2025-11-24 17:00U:BMYNews ReleaseBristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
2025-11-24 06:59U:BMYNews ReleaseBristol Myers Squibb to Host Hematology-Focused Investor Event
2025-11-18 14:25U:BMYNews ReleaseBristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
2025-11-17 22:33U:BMYNews ReleaseBristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers